戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  implicated in the pathogenesis of cutaneous polyarteritis nodosa (cPAN) and early-onset vasculopathy
2 noch-Schonlein purpura (HSP) and macroscopic polyarteritis nodosa (PAN) as early manifestations of Ig
3                                              Polyarteritis nodosa (PAN) has been used as a generic te
4                                              Polyarteritis nodosa (PAN) is a rare disease of childhoo
5                                              Polyarteritis nodosa (PAN) is regarded rightly as the gr
6 ment as a relatively common manifestation of polyarteritis nodosa (PAN), using the modern classificat
7  patients who developed vasculitis mimicking polyarteritis nodosa and giant cell arteritis.
8 is, and those of medium-vessel arteritis are polyarteritis nodosa and Kawasaki disease.
9 henotype, as well as two young siblings with polyarteritis nodosa and one patient with small-vessel v
10                        A study of idiopathic polyarteritis nodosa demonstrates greater similarity to
11                                 The study of polyarteritis nodosa has additionally been affected by p
12                                              Polyarteritis nodosa is a form of necrotizing vasculitis
13                                              Polyarteritis nodosa is a systemic necrotizing vasculiti
14 1 mutations, whereas the three patients with polyarteritis nodosa or small-vessel vasculitis were hom
15 's granulomatosis, inflammatory myopathy, or polyarteritis nodosa rather than rheumatoid arthritis, a
16 extracellular adenosine deaminase, can cause polyarteritis nodosa vasculopathy with highly varied cli
17 akayasu arteritis, giant cell arteritis, and polyarteritis nodosa) to atherosclerosis, display remark
18 aphy findings led to a clinical diagnosis of polyarteritis nodosa, and immunosuppressive therapy was
19  Wegener's granulomatosis, Cogan's syndrome, polyarteritis nodosa, and systemic lupus erythematosus.
20 age, treating Kawasaki disease, and treating polyarteritis nodosa, but most reported feeling comforta
21 ith multiple cases of systemic and cutaneous polyarteritis nodosa, consistent with autosomal recessiv
22 ication criteria for Wegener granulomatosis, polyarteritis nodosa, giant-cell arteritis, and hypersen
23  for vasculitis-related hospitalizations for polyarteritis nodosa, hypersensitivity vasculitis, Wegen
24  cytoplasmic antibody-associated vasculitis, polyarteritis nodosa, Kawasaki disease, giant cell arter
25 pathy (recurrent fevers, livedo reticularis, polyarteritis nodosa, lacunar ischemic strokes, and intr
26 ystemic vasculitides with neuropathy include polyarteritis nodosa, microscopic polyangiitis (MPA), rh
27 y in patients with Wegener's granulomatosis, polyarteritis nodosa, microscopic polyangiitis, and Chur
28 (relapsing polychondritis, Sweet's syndrome, polyarteritis nodosa, or giant-cell arteritis) or a hema
29 anulomatosis, polymyositis, dermatomyositis, polyarteritis nodosa, or scleroderma who had an emergent
30  of the first case of idiopathic vasculitis, polyarteritis nodosa, which even today is the basis of o
31 is of other primary vasculitides, especially polyarteritis nodosa.
32 man in her 50s with a diagnosis of cutaneous polyarteritis nodosa.
33  60% of Nppb-/- females developed mesenteric polyarteritis-nodosa (PAN)-like vasculitis in their life
34 tosis, microscopic polyangiitis (microscopic polyarteritis), the Churg-Strauss syndrome, idiopathic p
35 itis disorders (necrotizing arteritis of the polyarteritis type, hypersensitivity vasculitis, systemi